Latest Period
Q1 2026
Security Snapshot
Summit Therapeutics Inc. - COM (SMMT) Institutional Ownership
CUSIP: 86627T108
13F Institutional Holders and Ownership History from Q3 2020 to Q1 2026
Institutions Reporting
222
Shares (Excl. Options)
118,916,739
Price
$18.96
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COM
- Symbol
- SMMT on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 118,916,739
- Total 13F value
- $2,252,626,947
- Portfolio coverage rank
- 0%
- Share change
- +13,107
- Value change
- +$4,864,361
- Number of holders
- 222
- SEC-reported price per share
- $18.08
- Insider filing price
- $18.08
Latest holder snapshot
5 signals
Issuer context
Who this page is about.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- SMMT - Summit Therapeutics Inc. - COM is tracked under CUSIP 86627T108.
- 222 institutions reported positions in Q1 2026.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 206 to 222 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $2,060,259,964 to $2,252,626,947.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 222 institutions filings for Q1 2026.
Security key
86627T108
Latest holder period
Q1 2026
13F holders
222
13D/G owners
0
CIK / CUSIP context first
Open Q1 2026 holders
SMMT full holder history
Summit Therapeutics Inc. SEC filings
Summit Therapeutics Inc. company facts
Summit Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 86627T108:
As of 31 Mar 2026, 222 institutional investors reported holding 118,916,739 shares of Summit Therapeutics Inc. - COM (SMMT).
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
23
Latest
Q1 2026
Rows shown
1-23 of 23
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 118,916,739 | $2,252,626,947 | +$4,864,361 | $18.96 | 222 |
| 2025 Q4 | 117,788,001 | $2,060,259,964 | +$249,329,722 | $17.49 | 206 |
| 2025 Q3 | 102,790,902 | $2,124,233,076 | +$101,213,528 | $20.66 | 230 |
| 2025 Q2 | 97,848,320 | $2,079,803,739 | +$34,103,835 | $21.28 | 225 |
| 2025 Q1 | 97,733,829 | $1,887,229,142 | +$89,016,064 | $19.29 | 199 |
| 2024 Q4 | 92,613,844 | $1,652,162,078 | +$117,836,335 | $17.84 | 194 |
| 2024 Q3 | 84,474,771 | $1,848,145,011 | +$298,396,085 | $21.90 | 164 |
| 2024 Q2 | 72,164,786 | $562,895,901 | +$185,636,664 | $7.80 | 118 |
| 2024 Q1 | 49,654,473 | $205,842,486 | +$72,450,894 | $4.14 | 102 |
| 2023 Q4 | 32,347,368 | $84,434,113 | +$2,186,340 | $2.61 | 93 |
| 2023 Q3 | 32,310,209 | $60,420,216 | -$5,139,413 | $1.87 | 91 |
| 2023 Q2 | 34,903,696 | $87,605,995 | +$36,385,283 | $2.51 | 96 |
| 2023 Q1 | 21,131,959 | $36,976,249 | +$21,762,761 | $1.75 | 86 |
| 2022 Q4 | 8,101,933 | $34,536,890 | +$22,599,596 | $4.25 | 57 |
| 2022 Q3 | 3,172,802 | $3,773,379 | -$5,112,229 | $1.19 | 37 |
| 2022 Q2 | 8,456,620 | $8,456,000 | -$4,226,540 | $1.00 | 33 |
| 2022 Q1 | 10,947,648 | $26,824,000 | -$299,864 | $2.45 | 44 |
| 2021 Q4 | 11,033,765 | $29,678,000 | +$54,239 | $2.69 | 49 |
| 2021 Q3 | 10,933,895 | $54,779,617 | -$944,411 | $5.01 | 50 |
| 2021 Q2 | 11,040,017 | $82,356,721 | +$14,136,648 | $7.46 | 52 |
| 2021 Q1 | 9,283,184 | $54,489,348 | +$1,359,001 | $5.87 | 36 |
| 2020 Q4 | 9,061,824 | $42,589,259 | +$2,512,909 | $4.70 | 31 |
| 2020 Q3 | 7,749,222 | $26,750,440 | +$26,750,440 | $3.44 | 15 |